Clinical Research, Pharma & Healthcare FinancingAssembly Biosciences Doses First Participant in ABI-6250 StudyGlobeNewswireMarch 4, 2025March 18, 2025 by GlobeNewswireMarch 4, 2025March 18, 2025021 Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 Biomarker of ABI-6250 target...
